Get started

Pharmaceuticals

Healthcare is still in a bull market - be longAt the start of 2022, healthcare stocks have gotten killed, especially anything that was a winner in the past 1-2 years. A lot of people are getting rather bearish, but they shouldn't be. The fundamentals favor healthcare still in many ways, and momentum is still rather strong. We already got the breakout in healthcare stocks, and we just got the retest, which was enough to scare a lot of people out. Now is a great entry for a long position, coming out of a short consolidation into a potential new bull phase.
AMEX:XLVLong
by GTStockmaster
MRK has a lot of headline potential from hereHeadline Potential Merck has three drugs currently under priority FDA review, one of them a Covid-19 drug: Molnupiravir, an antiviral for Covid-19 which has received a positive opinion from the advisory board and which Merck's CEO says should work against any variant Vaxneuvance, a pneumococcal vaccine Lynparza, a breast cancer drug Merck also continues to make strong headway with Keytruda, an immunotherapy, which recently picked up another approval in Japan. All of this means that Merck has a lot of headline potential in coming weeks, especially at a time when a new Covid-19 variant is spreading across the world. There's quite a bit of options activity in Merck today as traders place bets ahead of the news. Technicals and Sentiment Merck is currently near support from a long-term trend line and from the 200-day EMA. It has 26% upside to the average analyst price target and a bullish put/call ratio of .43. It has an average analyst rating of 9.3/10, which is very high. It gets an above average ESG score of 2.25/3. Value S&P Global gives Merck's fundamentals an average score of 90/100. IIt's currently trading -1.4 standard deviations below where it usually trades in relation to its major moving averages. Forward dividend yield is about 3.7%, forward P/E just over 11, forward P/S about 3.4. The price to free cash flow ratio is fairly high, at over 20, but that has to be interpreted in light of the other multiples. estimate that Merck has about 18% upside to its average price multiple of the last 3 years. Its earnings outlook is highly positive; I score its growth forecast a 5/6.
NYSE:MRKLong
by ChristopherCarrollSmith
9
VRTX Long Chance on ChannelNASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago. For me its a very good chance and low price for VRTX. strong up move with good volume crossing the negative trend crossed EMA200 and MA200 on daily chart and also on weeky chart still above EMA200 and MA200 on monthly chart still in positive trend since 2008 good position in the market good cashflow for the next years, even if products are failing
NASDAQ:VRTXLong
by JulianRichard11
1
Biotech primed for a move higher?This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation here, and I really like the price action on it today. A lot of other sector funds have had mid-day pullbacks, but XBI has maintained its steady upward slope. It has poked above the 20-day EMA. My guess is that this will be green again tomorrow, so I've rolled the dice on a call expiring October 29. I'm also looking for continuation the next two weeks, with a first target of about 131.75.
AMEX:XBILong
by ChristopherCarrollSmith
17